BRNS vs PATH · rev $15.0M vs P/E 19, rev $1.61B
Barinthus Biotherapeutics plc (BRNS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BRNS revenue for 2024-12-31 was $15.0M. Net income was -$61.2M. Revenue was up 1766.5% from 2023-12-31 to 2024-12-31. BRNS currently screens at market cap $38.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BRNS currently screens at market cap $38.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BRNS and PATH stock pages for the full models.
Not investment advice.